# Xenetic Biosciences Inc. (XBIO)

Source: https://www.quantisnow.com/company/XBIO
Generated: 2026-11-22T16:27:22.407Z

- Ticker: XBIO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001534525
- Website: xeneticbio.com

## About

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

## Latest XBIO news and filings

- 2026-11-13 13:37 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-xenetic-biosciences-inc-6789569)
- 2026-11-13 13:35 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-results-of-operations-6789564)
- 2026-11-13 13:30 UTC [Market Insight] [Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates](https://www.quantisnow.com/insight/xenetic-biosciences-reports-third-quarter-2026-financial-results-and-highlights-6789527)
- 2026-11-12 22:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xenetic-biosciences-inc-6788696)
- 2026-11-12 20:41 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-xenetic-biosciences-inc-6787440)
- 2026-11-04 14:20 UTC [Market Insight] [Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance](https://www.quantisnow.com/insight/xenetic-biosciences-announces-oral-presentation-at-68th-ash-annual-meeting-6771746)
- 2026-10-15 12:46 UTC [Market Insight] [Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma](https://www.quantisnow.com/insight/xenetic-biosciences-and-periness-announce-first-patient-dosed-in-investigator-initiated-6747481)
- 2026-09-23 21:20 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-6724468)
- 2026-09-16 11:00 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-entry-into-a-6716877)
- 2026-09-16 11:00 UTC [Market Insight] [Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics](https://www.quantisnow.com/insight/xenetic-biosciences-and-santersus-ag-announce-definitive-share-exchange-agreement-6716860)
- 2026-08-07 12:35 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-results-of-operations-6670779)
- 2026-08-07 12:35 UTC [Market Insight] [Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform](https://www.quantisnow.com/insight/xenetic-biosciences-reports-second-quarter-2026-financial-results-and-highlights-6670775)
- 2026-08-06 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xenetic-biosciences-inc-6669552)
- 2026-06-04 12:40 UTC [Market Insight] [Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma](https://www.quantisnow.com/insight/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-6588744)
- 2026-06-01 13:02 UTC [Market Insight] [Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival](https://www.quantisnow.com/insight/xenetic-biosciences-showcases-compelling-asco-2026-data-demonstrating-dnase-i-6580979)
- 2026-05-14 20:47 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-xenetic-biosciences-inc-6554577)
- 2026-05-13 12:05 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-results-of-operations-6549817)
- 2026-05-13 12:05 UTC [Market Insight] [Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform](https://www.quantisnow.com/insight/xenetic-biosciences-reports-first-quarter-2026-financial-results-and-highlights-6549813)
- 2026-05-12 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xenetic-biosciences-inc-6548483)
- 2026-04-24 21:15 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-xenetic-biosciences-inc-6514995)
- 2026-04-24 21:00 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-leadership-update-financial-6514927)
- 2026-04-23 21:00 UTC [SEC Form 4] [Interim CEO and CFO Parslow James F was granted 100,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/interim-ceo-and-cfo-parslow-james-f-was-granted-100000-6513013)
- 2026-04-22 13:00 UTC [Market Insight] [Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting](https://www.quantisnow.com/insight/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-6509741)
- 2026-03-13 12:00 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-results-of-operations-6446115)
- 2026-03-13 12:00 UTC [Market Insight] [Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results](https://www.quantisnow.com/insight/xenetic-biosciences-inc-reports-full-year-2025-financial-results-6446097)
- 2026-03-12 21:00 UTC [SEC Form 10-K] [SEC Form 10-K filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-xenetic-biosciences-inc-6445236)
- 2026-02-12 19:15 UTC [SEC Form SCHEDULE 13G filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-xenetic-biosciences-inc-6389163)
- 2026-01-09 22:00 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-other-events-6344691)
- 2026-01-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Borisenko Grigory G.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-borisenko-grigory-g-6335636)
- 2026-01-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Dastoor Firdaus J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dastoor-firdaus-j-6335629)
- 2026-01-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Kornberg Roger D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kornberg-roger-d-6335627)
- 2026-01-05 22:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Vinogradov Alexey Andreevich](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-vinogradov-alexey-andreevich-6335625)
- 2025-12-11 22:01 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-xenetic-biosciences-inc-6312840)
- 2025-12-11 22:00 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-regulation-fd-disclosure-6312835)
- 2025-12-11 22:00 UTC [Market Insight] [Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting](https://www.quantisnow.com/insight/xenetic-biosciences-inc-announces-adjournment-of-2025-annual-meeting-6312818)
- 2025-11-19 13:45 UTC [Market Insight] [Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform](https://www.quantisnow.com/insight/xenetic-biosciences-inc-extends-research-and-development-collaboration-with-institute-6286363)
- 2025-11-13 13:45 UTC [SEC Form 8-K] [Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xenetic-biosciences-inc-filed-sec-form-8-k-results-of-operations-6276460)
- 2025-11-13 13:45 UTC [Market Insight] [Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results](https://www.quantisnow.com/insight/xenetic-biosciences-inc-reports-third-quarter-2025-financial-results-6276459)
- 2025-11-12 21:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xenetic-biosciences-inc-6274920)
- 2025-10-31 20:20 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Xenetic Biosciences Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-xenetic-biosciences-inc-6254657)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/XBIO
- Earnings history: https://www.quantisnow.com/earnings/XBIO
- Dividend history: https://www.quantisnow.com/dividends/XBIO
- Insider transactions: https://www.quantisnow.com/insiders/XBIO
- Options chain: https://www.quantisnow.com/options/XBIO
- SEC 8-K filings only: https://www.quantisnow.com/company/XBIO/8-k
- RSS and alerts for XBIO: https://www.quantisnow.com/docs/rss-feeds.md
